Northern Trust’s Acorda Therapeutics ACOR Stock Holding History

Northern Trust’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,956	Closed	-$22.9K	–	4631
2023 Q1	$22.9K	Buy	1,956 +650	+50%	+$10.8K	﹤0.01%	4423
2022 Q4	$20K	Hold	1,306	–	–	﹤0.01%	4488
2022 Q3	$8K	Hold	1,306	–	–	﹤0.01%	4657
2022 Q2	$12K	Sell	1,306 -25	-2%	-$444	﹤0.01%	4684
2022 Q1	$43K	Buy	1,331 +25	+2%	+$983	﹤0.01%	4569
2021 Q4	$62K	Sell	1,306 -25	-2%	-$1.72K	﹤0.01%	4554
2021 Q3	$123K	Sell	1,331 -129	-9%	-$10.7K	﹤0.01%	4350
2021 Q2	$140K	Sell	1,460 -15	-1%	-$1.31K	﹤0.01%	4276
2021 Q1	$144K	Buy	1,475 +691	+88%	+$84.9K	﹤0.01%	4198
2020 Q4	$65K	Sell	784 -294	-27%	-$27K	﹤0.01%	4198
2020 Q3	$67K	Sell	1,078 -25	-2%	-$1.89K	﹤0.01%	4055
2020 Q2	$97K	Sell	1,103 -3,595	-77%	-$380K	﹤0.01%	3930
2020 Q1	$526K	Sell	4,698 -3,336	-42%	-$657K	﹤0.01%	3437
2019 Q4	$1.97M	Sell	8,034 -458	-5%	-$116K	﹤0.01%	3141
2019 Q3	$2.92M	Buy	8,492 +215	+3%	+$117K	﹤0.01%	2870
2019 Q2	$7.62M	Buy	8,277 +217	+3%	+$267K	﹤0.01%	2317
2019 Q1	$12.9M	Sell	8,060 -306	-4%	-$551K	﹤0.01%	1985
2018 Q4	$15.6M	Sell	8,366 -73	-0.9%	-$159K	﹤0.01%	1773
2018 Q3	$19.9M	Sell	8,439 -309	-4%	-$957K	﹤0.01%	1804
2018 Q2	$30.1M	Buy	8,748 +64	+0.7%	+$196K	0.01%	1440
2018 Q1	$24.6M	Buy	8,684 +42	+0.5%	+$126K	0.01%	1521
2017 Q4	$22.2M	Sell	8,642 -133	-2%	-$378K	0.01%	1626
2017 Q3	$24.9M	Buy	8,775 +1,292	+17%	+$3.4M	0.01%	1552
2017 Q2	$17.7M	Buy	7,483 +2,952	+65%	+$5.85M	﹤0.01%	1765
2017 Q1	$11.4M	Buy	4,531 +89	+2%	+$256K	﹤0.01%	2029
2016 Q4	$10M	Buy	4,442 +164	+4%	+$390K	﹤0.01%	2119
2016 Q3	$10.7M	Buy	4,278 +87	+2%	+$260K	﹤0.01%	2024
2016 Q2	$12.8M	Sell	4,191 -217	-5%	-$706K	﹤0.01%	1850
2016 Q1	$14M	Buy	4,408 +65	+1%	+$270K	﹤0.01%	1740
2015 Q4	$22.3M	Buy	4,343 +106	+3%	+$463K	0.01%	1423
2015 Q3	$13.5M	Buy	4,237 +87	+2%	+$337K	﹤0.01%	1783
2015 Q2	$16.6M	Sell	4,150 -33	-0.8%	-$127K	0.01%	1728
2015 Q1	$16.7M	Buy	4,183 +65	+2%	+$298K	0.01%	1717
2014 Q4	$20.2M	Sell	4,118 -129	-3%	-$554K	0.01%	1536
2014 Q3	$17.3M	Sell	4,247 -22	-0.5%	-$82.5K	0.01%	1615
2014 Q2	$17.3M	Sell	4,269 -490	-10%	-$2M	0.01%	1627
2014 Q1	$21.6M	Sell	4,759 -251	-5%	-$1.01M	0.01%	1507
2013 Q4	$17.6M	Buy	5,010 +36	+0.7%	+$140K	0.01%	1632
2013 Q3	$20.4M	Sell	4,974 -69	-1%	-$297K	0.01%	1443
2013 Q2	$20M	Buy	+5,043	New	+$20.8M	0.01%	1386

Other funds holding ACOR

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Northern Trust's ACOR Position: Q2 2023 in Review

Northern Trust sold out of Acorda Therapeutics (ACOR) in Q2 2023, closing a stake of 1,956 shares — an estimated $22.9K sold.

Northern Trust first reported a position in ACOR in Q2 2013 and held it in 40 quarters. The position peaked at $30.1M in Q2 2018. 15 funds tracked by Wall St. Rank hold ACOR as of Q2 2023.

Northern Trust reported no remaining Acorda Therapeutics position as of Q2 2023 after selling out during the quarter.
Northern Trust sold 1,956 Acorda Therapeutics shares in Q2 2023, an estimated $22.9K.
Northern Trust first reported a position in Acorda Therapeutics in Q2 2013 and held it in 40 quarters.
Northern Trust's Acorda Therapeutics position peaked at $30.1M in Q2 2018.
15 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2023.

Based on Northern Trust's 13F filing for Q2 2023, filed 11 Aug 2023.